An explosion in the number of publicly listed biotech companies—in combination with these companies’ strong preference to hire almost exclusively from within the life sciences industry—has put intense pressure on the biotech CFO market. In short, the demand for CFOs with biotech companies’ ideal profile—high performers with a history of proven results and of sitting public CFO, IPO and biotech industry experience—simply outstrips supply.
Read the entire Russel Reynolds analysis here.
